VAUGHAN, Ontario / Aug 14, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two investor conferences in September:
Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in investor meetings at the J.P. Morgan conference. Chairman of the Board and Chief Executive Officer Brent Saunders and Sam Eldessouky will participate in a fireside chat at the Morgan Stanley conference.
A live webcast of the Morgan Stanley fireside chat will be available on the Investor Relations section of the Bausch + Lomb website.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.
© 2025 Bausch + Lomb
| Last Trade: | US$16.82 |
| Daily Change: | 0.01 0.06 |
| Daily Volume: | 225,343 |
| Market Cap: | US$5.960B |
November 13, 2025 November 03, 2025 October 29, 2025 September 11, 2025 September 09, 2025 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load